Quanterix Corporation

Dandan Shan

Linan Song

David Wilson

Lei Chang

Andreas Jeromin

Purvish Prahlad Patel

Edward Kevin Hrusovsky

Carmen Ioana Tobos

David C Duffy

Mingwei Zhao

The present disclosure relates to immunoassays for NF-L performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L determinations at concentrations indicative of the condition.

Quantification of neurofilament light chain in physiological samples

The present disclosure relates to immunoassays for NF-L, GFAP, UCH L1, and Tau performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L, GFAP, UCH L1, and Tau at concentrations indicative of the condition.

Quantification of biomarkers present in physiological samples

The present disclosure relates to digital immunoassays performed on diluted samples obtained from dried blood spots, for example dried capillary blood samples, to detect the presence or absence of a physiological condition by quantifying one or a combination of biomarkers at concentrations indicative of the condition.

Quantification of biomarkers present in dried physiological samples

Described herein are methods and systems for detecting DNA or RNA using single molecules array or other techniques. DNA or RNA from the sample may be fragmented and exposed to a first type of binding ligand and a second type of binding ligand that comprise nucleic acid sequences complimentary at least a portion of a sequence contained in the target DNA or RNA. At least a portion of the fragmented DNA or RNA associates with at least one of the first type of binding ligand and/or the second type of binding ligand, wherein the first type of binding ligand and second type of binding ligand comprises nucleic acid sequences complimentary to a different portions of a sequence contained in the DNA or RNA. A portion of the sample exposed to the binding ligands is analyzed to determine the number of fragmented DNA or RNA sequences.

Growing community of inventors

Acton, MA, United States of America

Dandan Shan